|
1
|
El-Serag HB and Rudolph L: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eguchi S, Kanematsu T, Arii S, Omata M,
Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M,
et al: Recurrence-free survival more than 10 years after liver
resection for hepatocellular carcinoma. Brit J Surg. 98:552–557.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lever AF, Hole DJ, Gillis CR, McCallum IR,
McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL and
Robertson JW: Do inhibitors of angiotensin-I-converting enzyme
protect against risk of cancer? Lancet. 352:179–184. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vinson GP, Barker S and Puddefoot JR: The
renin-angiotensin system in the breast and breast cancer. Endocr
Relat Cancer. 19:R1–R19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wilop S, von Hobe S, Crysandt M, Esser A,
Osieka R and Jost E: Impact of angiotensin I converting enzyme
inhibitors and angiotensin II type 1 receptor blockers on survival
in patients with advanced non-small-cell lung cancer undergoing
first-line platinum-based chemotherapy. J Cancer Res Clin.
135:1429–1435. 2009. View Article : Google Scholar
|
|
6
|
Petty WJ, Miller AA, McCoy TP, Gallagher
PE, Tallant EA and Torti FM: Phase I and pharmacokinetic study of
angiotensin-(1–7), an endogenous antiangiogenic hormone. Clin
Cancer Res. 15:7398–7404. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hallas J, Christensen R, Andersen M, Friis
S and Bjerrum L: Long term use of drugs affecting the
renin-angiotensin system and the risk of cancer: A population-based
case-control study. Brit J Clin Pharmaco. 74:180–188. 2012.
View Article : Google Scholar
|
|
8
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Y, Li B, Wang X, Li G, Shang R, Yang
J, Wang J, Zhang M, Chen Y, Zhang Y, et al: Angiotensin-(1–7)
suppresses hepatocellular carcinoma growth and angiogenesis via
complex interactions of angiotensin II type 1 receptor, angiotensin
II type 2 receptor and mas receptor. Mol Med. 21:626–636. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou L, Xue H, Wang Z, Ni J, Yao T, Huang
Y, Yu C and Lu LM: Angiotensin-(1–7) attenuates high
glucose-induced proximal tubular epithelial-to-mesenchymal
transition via inhibiting ERK1/2 and p38 phosphorylation. Life Sci.
90:454–462. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Santhekadur PK, Akiel M, Emdad L, Gredler
R, Srivastava J, Rajasekaran D, Robertson CL, Mukhopadhyay ND,
Fisher PB and Sarkar D: Staphylococcal nuclease domain containing-1
(SND1) promotes migration and invasion via angiotensin II type 1
receptor (AT1R) and TGF-β signaling. FEBS Open Bio. 4:353–361.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Passos-Silva DG, Verano-Braga T and Santos
RA: Angiotensin-(1–7): Beyond the cardio-renal actions. Clin Sci
(Lond). 124:443–456. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Menon J, Soto-Pantoja DR, Callahan MF,
Cline JM, Ferrario CM, Tallant EA and Gallagher PE:
Angiotensin-(1–7) inhibits growth of human lung adenocarcinoma
xenografts in nude mice through a reduction in cyclooxygenase-2.
Cancer Res. 67:2809–2815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Assimes TL, Elstein E, Langleben A and
Suissa S: Long-term use of antihypertensive drugs and risk of
cancer. Pharmacoepidemiol Drug Saf. 17:1039–1049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kinoshita J, Fushida S, Harada S, Yagi Y,
Fujita H, Kinami S, Ninomiya I, Fujimura T, Kayahara M, Yashiro M,
et al: Local angiotensin II-generation in human gastric cancer:
Correlation with tumor progression through the activation of
ERK1/2, NF-kappa B and survivin. Int J Oncol. 34:1573–1582. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Attoub S, Gaben AM, Al-Salam S, Al Sultan
MA, John A, Nicholls MG, Mester J and Petroianu G: Captopril as a
potential inhibitor of lung tumor growth and metastasis. Ann N Y
Acad Sci. 1138:65–72. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wani S and Sharma P: The role of
chemoprevention in Barrett esophagus and esophageal adenocarcinoma.
J Clin Gastroenterol. 41 Suppl:S135–S140. 2007. View Article : Google Scholar
|
|
18
|
Arrieta O, Villarreal-Garza C, Vizcaino G,
Pineda B, Hernandez-Pedro N, Guevara-Salazar P, Wegman-Ostrosky T,
Villanueva-Rodriguez G and Gamboa-Dominguez A: Association between
AT1 and AT2 angiotensin II receptor expression with cell
proliferation and angiogenesis in operable breast cancer. Tumor
Biol. 36:5627–5634. 2015. View Article : Google Scholar
|
|
19
|
George AJ, Thomas WG and Hannan RD: The
renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev
Cancer. 10:745–759. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zong H, Yin B, Zhou H, Cai D, Ma B and
Xiang Y: Loss of angiotensin-converting enzyme 2 promotes growth of
gallbladder cancer. Tumor Biol. 36:5171–5177. 2015. View Article : Google Scholar
|
|
22
|
Qi MH, Ye J and Qi ZY: Angiotensin II
induces hepatocellular carcinoma cell line SMMC-7721 to produce
epithelial mesenchymal transition. Guangdong Med J. 36:1–3.
2015.(In Chinese).
|
